SectorPharmaceutical
Established Date--
Listing Date29/03/2018
ExchangeNASDAQ Stock Exchange
Full-time Employees258
Fiscal Year Ends31/12
Security TypeCommon stock
Office address275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451
Business
IntroductionCogent Biosciences, Inc., was incorporated in March 2014 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing precision therapies for hereditary diseases. The company's approach is to design reasonable precision therapies that treat the root causes of disease and improve the lives of patients. The company's most advanced project is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to effectively inhibit KIT D816V mutations and other mutations in KIT exon 17.
